HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice

Conclusions The A876P-substitution bridges in vitro and in vivo studies using J6/JFH1-based recombinants. We provide the first in vivo evidence that HVR1 protects cross-genotype conserved HCV neutralisation epitopes, which advocates the possibility of using HVR1-deleted viruses as vaccine antigens to boost broadly reactive protective nAb responses.

http://gut.bmj.com/cgi/content/short/65/12/1988?rss=1

Source: Gut - November 8, 2016 Category: Gastroenterology Authors: Prentoe, J., Verhoye, L., Velazquez Moctezuma, R., Buysschaert, C., Farhoudi, A., Wang, R., Alter, H., Meuleman, P., Bukh, J. Tags: Open access Hepatology Source Type: research